Excellence Strategy

Department of Preclinical Imaging and Radiopharmacy

The Department of Preclinical Imaging and Radiopharmacy, consisting of the Werner Siemens Imaging Center and the associated Radiopharmacy, offers unique scientific and infrastructural potential worldwide. This is where the latest innovations in the areas of imaging procedures, image processing, detector technology and the preclinical development of novel clinical diagnostic and treatment concepts for the clinic are bundled.

 

Running projects

Hybrid imaging using PET and fMRI to investigate the functional connectivity of the brain

The brain is the most complex organ in humans. Its primary units, the neurons, communicate with each other and are organized in networks. Characterizing these neuronal circuits is of great interest to science, and the ability to modulate circuit nodes and control neuronal functions using optogenetic tools has revolutionized research. In the research group of Prof. Kristina Herfert, various stimulation techniques are used to investigate their effects on the functional, metabolic, and molecular connectivity of the brain in both healthy and pathological conditions

 

Advanced preclinical metabolic imaging and cell engineering

Cell metabolism plays a crucial role in understanding nutrient uptake and the oxidation of key substrates in tissues. Prof. André Martins' research group addresses the biochemical/biomedical challenge of visualizing these processes by utilizing cutting-edge and translational metabolic imaging to develop new targeted and image-guided therapies for cancer, diabetes, stroke, and liver failure

 

Preclinical imaging of the immune system

Immunotherapies currently represent one of the most promising approaches for treating advanced cancers, with the potential to induce long-lasting regression and even cure. Unfortunately, solid tumors respond to these immunotherapies with varying degrees of success. Prof. Bettina Weigelin's research group combines advanced microscopic techniques with state-of-the-art macroscopic imaging to gain mechanistic insights into the kinetics and function of immunotherapies at both the cellular and whole-body level. Visualizing the response of immunotherapy in living tumor tissue over time enables the identification of tissue-specific resistance niches and approaches for improved cancer immunotherapies

 

New Checkpoint-Inhibitor Therapies

The success of strategies to induce antitumor immune responses through checkpoint inhibition or adoptive T cells has led to a clinical paradigm shift in conventional cancer therapy. Dr. Dominik Sonanini's research group focuses on the development and application of novel imaging probes that can be used for patient stratification, elucidation of early treatment responses, and the implementation of rational combinatory immunotherapy approaches. In particular, the so-called ImmunoPET offers a direct imaging strategy that combines positron emission tomography (PET) isotopes with targeted antibodies (Abs), engineered fragments, or small molecules capable of non-invasively monitoring the expression of cancer and immune cell biomarkers.